Ulcerative colitis and Crohn's disease are the two predominant types of inflammatory bowel disease (IBD), affecting over 1.4 million individuals in the United States. IBD results from complex interactions between pathogenic components, including genetic and epigenetic factors, the immune response, and the microbiome, through an unknown sequence of events. The purpose of this review is to describe a systems biology approach to IBD as a novel and exciting methodology aiming at developing novel IBD therapeutics based on the integration of molecular and cellular 'omics' data.
INTRODUCTION
Inflammatory bowel disease (IBD) is a multifactorial disease with several components contributing to its pathogenesis [1] . Alterations in the gut microbiota [2-4,5 && ], activation of different immune cell types [6] [7] [8] , changes in the vascular endothelium [9 & ,10] , and alterations in the structure of tight junctions in colonocytes [11] [12] [13] perturb the gut cellular interactome resulting in IBD development. Each cell population in the gut has its own complex molecular interactions (interactome), consisting of genetic, epigenetic, transcriptional, protein, and secreted factors. The isolated modulation of one component in the cellular and molecular gut interactomes might be insufficient to provide an effective therapeutic solution for IBD patients. A major problem that researchers in the IBD field face is how to integrate the continuously generated data derived from novel technologies and collectively characterize and quantitate the roles, relationships, and actions of various types of molecules, referred to as 'omics', and develop novel therapeutics that would target these interactomes instead of a specific signaling pathway or cellular population. In the last 5 years, the explosion in the development of novel computational and high-throughput technologies [14, 15] has enabled us to study different human diseases in a genome-wide level. Here, we will discuss how these technologies, through integration of high-throughput cellular, molecular, and clinical data, could contribute to our understanding of
SYSTEMS APPROACH IN INFLAMMATORY BOWEL DISEASE
A system is an entity that maintains its existence through the interactions of its parts. A systems approach consists of four major steps: identify the parts of the system; characterize the properties of the parts; identify the interaction between the parts; and evaluate the interactions between the parts and the environment [16] . A systems approach can be applied in IBD, aiming at identifying and understanding the complex interactions between different cell types (parts) in the gut (system), and determine whether these interactions are deregulated during IBD pathogenesis. The development of high-throughput technologies to analyze the entire set of genes (genome), epigenetic modifications (epigenome) and transcriptional regulation (transcriptome), and the identification of novel algorithms and software able to integrate the 'omics' data enabled the genesis of the systems biology field. During IBD development, there are perturbations of the molecular and cellular gut interactomes. In this review, we will present the state-of-the-art highthroughput technologies that are available to study the IBD interactomes and describe novel computational tools able to integrate the 'omics' information. The systems biology strategy is very promising aiming to expedite the drug discovery process in IBD.
MOLECULAR SYSTEMS APPROACH IN INFLAMMATORY BOWEL DISEASE
Previous studies have revealed the significance of genetic variations in IBD pathogenesis by performing large genome-wide association studies (GWAS) [17] . However, the genetic variants that have been associated with ulcerative colitis and Crohn's disease can only explain 20-25% of all IBD cases, suggesting the presence of additional contributing factors [18] . One of the striking aspects of IBD is its substantially increased incidence during the last decades, suggesting the potential involvement of environmental (epigenetic) factors in IBD pathogenesis [19] . Moreover, the completion of the ENCODE project last year [20] identified more than 100 000 novel transcripts that may be involved in IBD development. To build and characterize the IBD molecular interactome, we should first characterize its components ( Fig. 1 ) and then identify their complex interactions, by performing computational analysis.
Characterization of the inflammatory bowel disease genome
Genomics is defined as the study of genetic alterations in the genome-wide level. GWAS has been
KEY POINTS
Integration of molecular and cellular 'omics' is needed for a systems approach in IBD.
Development of novel therapeutics by targeting the central hubs of the IBD network.
To build IBD interactome, we should characterize its components and identify their interactions.
The drug-molecular interactome map will link chemical compounds to IBD molecular networks.
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Transcr ipts Genes FIGURE 1. Components of the molecular interactome. The molecular interactome consists of alterations at the genomic, transcriptomic, proteomic, and secretomic level. In this interactome, there are coding genes translated into proteins and noncoding genes, such as microRNAs and lincRNAs, functioning as RNA molecules in the cell. There are multiple complex interactions between transcripts, protein complexes, and metabolites.
performed in large numbers of IBD patients, resulting in the identification of novel variants [21] . Recently an assay, called ImmunoChip, has been developed including 200 000 single nucleotide polymorphisms (SNPs) relevant to IBD and other immune-mediated diseases [22] . Studies of SNPs and insertion-deletion polymorphisms identified a total of 163 loci associated with IBD and revealed important pathways involved in IBD pathogenesis such as host-microbe interactions and autophagy [5 && ,21] . These studies identified genomic regions that influence the risk of disease but cannot on their own determine specific causative roles. In fact, from the 163 loci only a handful has shown functional IBD-associated SNPs [23] . Exome sequencing analysis is informative for the whole spectrum of variation within the protein coding sequence of genes and carries the potential of identifying the missing heritability in complex diseases such as IBD. Recently, whole exome sequencing (the sequencing of the complete coding regions of the genome) applied in Crohn's disease and pediatric IBD patients revealed novel low-frequency variants in known IBD genes [24, 25] . Although all these approaches have contributed significantly to our knowledge of genetic alterations in IBD patients, up to date there is no study of sequencing the whole genome of IBD patients. This analysis will provide a comprehensive view of genetic alterations in IBD patients and potentially will identify novel SNPs and mutations in the genome of IBD patients.
Studying the inflammatory bowel disease epigenome
In addition to the genomic analysis, modifications could occur in the epigenetic level, affecting gene expression. Epigenetics is defined as cellular information that is heritable during cell division but is not encoded in the sequence of the genome. Pathologic epigenetic changes, such as DNA methylation and histone modifications, are increasingly considered as alternatives to mutations and chromosomal alterations in altering gene function [26] .
Inflammatory bowel disease DNA methylome
The increasing interest of the role of DNA methylation in IBD pathogenesis coincides with advances in platform-based DNA methylation array technologies. Employment of the Illumina 27K chip to analyze peripheral blood samples revealed 50 genes that were differentially methylated between patients with Crohn's disease and controls [27, 28] . Furthermore, another study in 20 monozygotic twins discordant for ulcerative colitis identified 61 differentially methylated loci, including genes involved in inflammation [29 && ]. However, none of these array technologies are able to study the DNA methylome at a genome-wide level. On the other hand, the DNA methylation-sequencing methodology will reveal the global DNA methylation alterations in IBD patients. A recently developed technology, called reduced representation bisulfite sequencing [30] , requires low RNA amounts (10 ng), even from paraffin-embedded samples, and is highly applicable to a wide range of IBD clinical samples.
Inflammatory bowel disease chromatin state
In addition to DNA methylation, histone modifications play a critical role in gene regulation by affecting chromatin packaging. A recent study revealed that cytokines could induce chromatin modifications in COL1A2 gene in intestinal mucosal endothelial cells [31 && ]. Global histone modifications have been extensively studied in cancer and neurodegenerative diseases but despite evidence on their role in inflammation, their genome-wide distribution and function in IBD are still unknown. To follow a systems biology approach, it is essential to perform chromatin immunoprecipitation-sequencing (ChIP-seq) analysis for active and suppressive chromatin marks in tissues and blood from IBD patients.
Evaluation of the inflammatory bowel disease transcriptome
The genome-wide expression catalogs the complete set of RNA transcripts, called transcriptome, produced by the genome, including coding and noncoding RNAs. cDNA microarray has been the main tool used to profile the global gene expression in IBD tissues or blood. Previous studies have identified a gene signature in ulcerative colitis patients that correlates with disease activity [32] . In addition to the coding genes, recent evidence suggested the presence of noncoding RNAs in the human genome, including microRNAs and large intergenic noncoding RNAs (lincRNAs) [20] . By employing microRNA expression arrays and use of novel microRNA highthroughput profiling platforms, such as Nanostring [33] , microRNAs such as miR-23a, miR-21, miR-29a, miR-124, and miR-192 have been found to be deregulated in colonic tissues and blood from IBD patients, and investigation of their mechanistic implications is currently underway [34,35 && , 36, 37] . To date there is no study regarding the potential role of lincRNAs in IBD pathogenesis. Future studies should perform integrated expression analysis of coding and noncoding RNAs in IBD patients by Systems biology in inflammatory bowel diseases Polytarchou et al.
using the RNA-sequencing technology [38] . This technology will reveal all the transcript variants that are potentially involved in IBD pathogenesis.
Revealing the inflammatory bowel disease proteome
Proteome is the complete set of expressed proteins, including their different isoforms and modifications. The proteome corresponds to the structure and function of proteins and their higher-order complexes as well as their localization and translocation [39, 40] . A wide selection of proteomic approaches has been applied to characterize IBD pathogenesis by investigating the dynamic nature of the proteome [41] , including surface-enhanced laser desorption ionization or matrix-assisted laser desorption-time of flight mass spectrometry (MS) and liquid chromatography (LC/MS) combined with two-dimensional gel electrophoresis. Such proteomic studies have been performed for IBD using epithelial cell lines [42] [43] [44] , epithelial cells from colonic biopsies [45] [46] [47] , and serum samples [48] [49] [50] [51] . Currently, the greatest interest in proteomic applications lies in identifying biomarkers in biofluids (such as serum and urine) or tissue samples (such as colonic biopsies) [41] that are specific for ulcerative colitis and Crohn's disease diseases and correlate with disease activity and other clinicopathological parameters.
Constructing the inflammatory bowel disease metabolome
The metabolome encompasses all the small molecules chemically transformed during cellular metabolism and provides a readout of cellular biochemistry [52, 53] . The analytical techniques used to study the metabolome include gas chromatography (GC), LC, and high/ultra-performance liquid chromatography (H/UPLC) followed by MS, and NMR [54] . Different metabolomic approaches have been applied in human biomaterials, including fecal water extracts, blood serum, and urine samples, aiming to discriminate IBD patients from control subjects [55] [56] [57] [58] [59] [60] [61] [62] . Furthermore, 1 H NMR spectroscopy and LC-MS have revealed distinct metabolic profiles between different intestinal compartments [63] . These data are very promising, suggesting the deregulation of the metabolome during IBD pathogenesis. Additional studies should determine the significance of these findings in large cohorts of IBD patients, aiming to develop prognostic and diagnostic tests in the near future. It is essential to integrate the proteomic and metabolomics data from IBD patients in order to fully characterize the biochemical map and its alterations during IBD development.
INTEGRATION OF INFLAMMATORY BOWEL DISEASE 'OMICS' DATA
Although there is a continuous generation of molecular 'omics' data from biomaterials derived from IBD patients, there is a major challenge on how to analyze and integrate these data in order to identify the central regulators of IBD pathogenesis. Network analysis could contribute to the construction of the IBD molecular interactome [64] . Network theory is a branch of applied mathematics that uses the concepts of graph theory [65, 66] . The development of network theory was led by applications to real-world examples, such as social networks and technological (Internet) networks. The structure of complex molecular interactions in IBD can be represented by networks and not by linear signaling pathways, a methodology followed by most researchers today. A network could reveal the positive and negative feedback loops and information exchange between the different signaling pathways. Overlooking the loop circuits led to several failures of drugs developed by pharmaceutical companies [67] . In an IBD network, nodes could correspond to genes, proteins, or metabolites, whereas the edges will represent the interactions, causal influences, or correlations between them (Fig. 2) . To detect the central molecular regulators in IBD pathogenesis, the IBD network could be compared to random graphs with defined statistical properties [68] . We can build networks based on the specific characteristics described above. For example, we can build an IBD metabolic network of the metabolites deregulated in IBD patients and the chemical reactions that connect these metabolites. An IBD transcriptional network can be constructed by identifying transcriptional interactions between deregulated coding and noncoding RNAs. A protein network will include the deregulated protein-protein interactions in specific cell types. The next step would be to integrate all these networks aiming to construct the IBD molecular interactome.
INFLAMMATORY BOWEL DISEASE NETWORK CONSTRUCTION AND VISUALIZATION
An important question is how practically could we construct and visualize these IBD molecular networks? The first step would be the generation of the 'omics' data from IBD patient biomaterials. Next, the dynamics and regulatory patterns of the potential gene, protein and metabolite interactions should be described by a mathematical graph. The graph could be constructed using Boolean network analysis, Bayesian network analysis, ordinary and partial differential equation systems, or stochastic processes [69] [70] [71] [72] [73] . A graph consists of a discrete set of nodes (N) and edges (E), which are defined as pairs of nodes (Fig. 2 ). The nodes could be genes, proteins, or metabolites deregulated in IBD, and the edges will show direct or indirect interactions between the nodes. Each network will be characterized by its statistical properties [74] . The node that shares an edge with another node is called neighbor, and the number of neighbors is called the degree or node size (k). A distinction between in-degrees (k in ) and out-degrees (k out ) refers to incoming and outgoing edges, respectively. The gene, protein, or metabolite with the high number of incoming and outgoing edges is called central regulator or hub [75] . The hubs identified by network analysis could be used as IBD drug targets because they will be central regulators of the IBD networks.
In the last few years, multiple software programs have been developed for systems biology purposes. A visit to the software guide at www.sbml.org website will reveal more than 100 different softwares developed for network and modeling analyses. JSIM is a Java-based software able to build IBD quantitative networks and can be used from a web browser [76] . In addition, the CellDesigner is another Java-based tool that could show visually appealing graphical representations of the IBD networks [77] . Furthermore, E-Cell is a Python-based software able to model, simulate, and analyze large-scale IBD networks and systems [78] . These tools require high knowledge of mathematics and computer programming, revealing the importance of integrating computational biologists in IBD research. In addition to computational tools, there are commercially available tools that do not require computing knowledge. A user-friendly software, called Ingenuity Pathway Analysis (IPA), constructs molecular networks based on experimental and literature-based data [79] . These computational tools can integrate molecular 'omics' data into networks for each of the cellular populations involved in IBD pathogenesis.
CELLULAR SYSTEMS APPROACH IN INFLAMMATORY BOWEL DISEASE
Gut physiology is maintained through balance between the epithelial, immune, endothelial cells, fibroblasts, and microbes. Mucosal immunity is an important component of IBD pathogenesis; however, it is only a part of the IBD cellular interactome. Gut microbiota can affect the function of regulatory T cells in the gut, contributing to IBD pathogenesis, while the proportion of the different luminal bacterial species changes significantly in IBD [80, 81] . Investigating the changes in the number and the identity of the microbiome in IBD patients has revealed distinct patterns that could be linked to disease pathogenesis [82, 83] . Lately, studies have focused on the functional consequences of IBDassociated dysbiosis. Using a novel technique to isolate the microbes and the proteins [84] or the metabolites [85 && ] from specific areas of the colon, investigators have shown an interdependence and a bi-directional influence of certain bacteria populations with specific pathways, thus identifying potentially important host-microbe interactions in IBD pathogenesis.
Recent evidence showed the importance of vascular and lymphatic endothelium in IBD pathogenesis. Blocking intestinal angiogenesis has a beneficial effect in experimental colitis [86] , while inhibition of a major lymphangiogenic receptor exacerbates colonic inflammation [87] . Novel studies contribute to our understanding on the role of colonic epithelial cells and tight junction structure and function in IBD pathogenesis [88] [89] [90] . Thus, it is essential to continue characterizing these cellular populations and identify their molecular links, aiming at constructing the IBD cellular interactome. The construction of the IBD cellular interactome should follow the same principles described for the IBD molecular interactome. This will be realized by integrating the molecular networks in each of the gut components (cells, microbes) and constructing a larger network that will reveal interactions between these different components. The nodes in this network that link two different gut components would reveal how a perturbation in one component would affect the dynamics and properties of another component.
INFLAMMATORY BOWEL DISEASE DRUG DISCOVERY AND SYSTEMS APPROACH
Although different cells and microbes are involved in IBD pathogenesis, modulation of one of these components alone may not lead to an IBD cure. The mucosal immune system has been the focus of multiple therapeutic interventions in IBD; however, the degree of success varies [18] . Alterations of the gut microbiota by probiotics have been used in IBD studies, but the benefits are variable and, more importantly, not permanent. Thus, it is becoming more evident that manipulation of a specific cellular or microbial population in the gut may not lead to an IBD cure. Because the different cellular and microbial components are parts of the IBD cellular interactome, identification of drugs perturbing the IBD cellular interactome using systems biology approaches may have a greater therapeutic potential. We propose to develop an IBD drug-molecular interactome map in the near future, based on the connectivity map platform [91] . This software tool will merge drug response hub signatures with the IBD interactome data, linking for the first time chemical compounds to IBD molecular networks. This methodology could potentially identify novel and highly specific IBD drug targets that could expedite the IBD drug development process.
CONCLUSION
Taken together, it is essential in the near future to establish an IBD Interactome Consortium through collaboration between top IBD research centers in various countries. This consortium should generate extensive 'omics' knowledge from biomaterials (tissue, blood, urine, and stool) derived from a well-characterized IBD cohort of patients, aiming to construct the IBD interactome in the near future, expediting the development of novel drugs for IBD patients through targeting the essential networks in this interactome. We should take advantage of the exciting discoveries in the biomedical technology field and transform them in novel therapeutics for IBD patients.
